PCSK9 : A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?
Copyright © 2018. Published by Elsevier B.V..
Atherosclerosis is characterized by chronic inflammation and lipid accumulation in arterial walls, resulting in several vascular events. Proprotein convertase subtilisin kexin 9 (PCSK9), a serine protease, has a pivotal role in the degradation of hepatic low-density lipoprotein receptor (LDLR). It can increase plasma concentrations of low-density lipoprotein cholesterol and affect lipid metabolism. Recently, PCSK9 has been found to accelerate atherosclerosis via mechanisms apart from that involving the degradation of LDLR, with an emerging role in regulating the inflammatory response in atherosclerosis. Apolipoprotein E receptor 2 (apoER2), one of the LDLR family members expressed in macrophages, can bind to its ligand apolipoprotein E (apoE), exhibiting an anti-inflammatory role in atherosclerosis. Evidence suggests that apoER2 is a target of PCSK9. This review aims to discuss PCSK9 as a potential regulator of apoE/apoER2 against inflammation in atherosclerosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:483 |
|---|---|
| Enthalten in: |
Clinica chimica acta; international journal of clinical chemistry - 483(2018) vom: 03. Aug., Seite 192-196 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bai, Xue-Qin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.10.2018 Date Revised 04.10.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cca.2018.04.040 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283748206 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283748206 | ||
| 003 | DE-627 | ||
| 005 | 20231225041622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cca.2018.04.040 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0945.xml |
| 035 | |a (DE-627)NLM283748206 | ||
| 035 | |a (NLM)29727700 | ||
| 035 | |a (PII)S0009-8981(18)30207-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bai, Xue-Qin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PCSK9 |b A potential regulator of apoE/apoER2 against inflammation in atherosclerosis? |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2018 | ||
| 500 | |a Date Revised 04.10.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018. Published by Elsevier B.V. | ||
| 520 | |a Atherosclerosis is characterized by chronic inflammation and lipid accumulation in arterial walls, resulting in several vascular events. Proprotein convertase subtilisin kexin 9 (PCSK9), a serine protease, has a pivotal role in the degradation of hepatic low-density lipoprotein receptor (LDLR). It can increase plasma concentrations of low-density lipoprotein cholesterol and affect lipid metabolism. Recently, PCSK9 has been found to accelerate atherosclerosis via mechanisms apart from that involving the degradation of LDLR, with an emerging role in regulating the inflammatory response in atherosclerosis. Apolipoprotein E receptor 2 (apoER2), one of the LDLR family members expressed in macrophages, can bind to its ligand apolipoprotein E (apoE), exhibiting an anti-inflammatory role in atherosclerosis. Evidence suggests that apoER2 is a target of PCSK9. This review aims to discuss PCSK9 as a potential regulator of apoE/apoER2 against inflammation in atherosclerosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Apolipoprotein E | |
| 650 | 4 | |a Apolipoprotein E receptor 2 | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Proprotein convertase subtilisin kexin 9 | |
| 650 | 7 | |a Apolipoproteins E |2 NLM | |
| 650 | 7 | |a LDL-Receptor Related Proteins |2 NLM | |
| 650 | 7 | |a low density lipoprotein receptor-related protein 8 |2 NLM | |
| 650 | 7 | |a PCSK9 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 650 | 7 | |a Proprotein Convertase 9 |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 700 | 1 | |a Peng, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Mei-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Qiong |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Zhong |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Hong-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Zhi-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Zhi-Han |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lu-Shan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinica chimica acta; international journal of clinical chemistry |d 1956 |g 483(2018) vom: 03. Aug., Seite 192-196 |w (DE-627)NLM000002054 |x 1873-3492 |7 nnns |
| 773 | 1 | 8 | |g volume:483 |g year:2018 |g day:03 |g month:08 |g pages:192-196 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cca.2018.04.040 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 483 |j 2018 |b 03 |c 08 |h 192-196 | ||